Advertisement
Before coming to Prolog, Broderick was a managing director at Mason Wellsin Milwaukee, WI, where he served on its board of directors and managementcommittee and managed the Mason Wells Biomedical Fund -- the firm's firstventure capital fund. Prior to this, he spent 18 years at the Mayo Clinic inRochester, MN, where he served as director of technology commercialization for12 years and co-launched the clinic's corporate venture capital fund.
Advertisement
"Dan's extensive industry experience and deal flow connections furtherstrengthen Prolog's expertise in early-stage life science investing," saidIlya Nykin, managing director of Prolog. "He was involved in the creation,financing, and growth of more than 20 venture-backed companies in Prolog'score areas of focus, most of them early-stage. Having Dan on Prolog's team isa great boost to our mission of translating life science breakthroughs intosuccessful ventures."
Broderick's professional accomplishments have prompted a number ofprominent industry boards and advisory panels to seek his involvement. He isa member of the board of directors of the National Venture Capital Associationand the chair of its Research Committee; a trustee of both the Medical Collegeof Wisconsin and the University of Wisconsin-Milwaukee Research Foundations; amember of the University of Minnesota Business Development Advisory Board; anda charter member of the venture capital advisory board of BioGenerator, a St.Louis nonprofit seed-capital investment fund.
"Not only is Dan an astute investor, but he is also a long-time colleague.We have an excellent track record of working together," said Greg Johnson,managing director of Prolog. "I met Dan 15 years ago, and over the years,we've collaborated on a number of investment opportunities. Our relationshipexpanded further in 2002 when we co-founded the Mid America HealthcareInvestor Network (MHIN), an organization of more than 50 venture capital fundsthat focus on life science opportunities." MHIN is now recognized as one ofthe most active and productive venture capital associations in the country.
It was through MHIN that Broderick developed a close rapport with Prolog'sother partners -- Ilya Nykin and Brian Clevinger. After Broderick's fundinvested in ZyStor Therapeutics, one of the most promising ventures inProlog's portfolio, he joined Clevinger on the company's board of directors.The two also have served together at several industry organizations includingBioGenerator, InvestMidwest, and BIO Mid-America Venture Forum.
"I was attracted to Prolog because it has one of the most innovative andeffective investment teams in the venture capital business," said Broderick."I especially admire this firm for being committed since inception tobalancing traditional healthcare investing with focused and resourcefulpursuit of opportunities in emerging areas of life science. I am convincedthis investment approach is the wave of the future and am excited to help thefirm build on its early leadership position."
Prolog is a venture capital firm specializing in life science investing.Since its launch in 2001, Prolog has financed more than 20 early-stagecompanies. The firm is managed by a team of professionals with extensiveexperience as both investors and entrepreneurs. Prolog focuses on traditionalhealthcare opportunities as well as emerging areas - such as nutrition,wellness, plant science, and enabling platforms - in which it has built one ofthe largest portfolios in the country. For more information, visitwww.prologventures.com.
SOURCE Prolog Vent
